Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares up 10 Percent on Lung Cancer Biomarker Data

NEW YORK, April 19 (GenomeWeb News) - Shares in Sequenom were trading up 10.3 percent, or $.10, at $1.11 in early afternoon trading on news that the company has developed a process to identify epigenetic markers in lung cancer.

 

The process performs high-throughput DNA methylation analysis based on Sequenom's MassArray system, the company said in a statement.

 

As described in a late-breaking poster at the American Association for Cancer Research meeting in Anaheim, Calif., Sequenom in collaboration with University of Liverpool researchers evaluated the performance of the procedure in a clinical setting by analyzing the cytosine methylation pattern in non-small cell lung cancer.

 

Shares of Sequenom reached a morning high of $1.20 immediately following the news, but have since dipped to their current level.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.